CSIMarket
 
Adlai Nortye Ltd   (ANL)
Other Ticker:  
 
 
Price: $2.1850 $0.15 7.108%
Day's High: $2.27 Week Perf: 5.05 %
Day's Low: $ 2.10 30 Day Perf: 10.35 %
Volume (M): 13 52 Wk High: $ 15.55
Volume (M$): $ 28 52 Wk Avg: $4.03
Open: $2.18 52 Wk Low: $1.85



 Market Capitalization (Millions $) 95
 Shares Outstanding (Millions) 43
 Employees 50
 Revenues (TTM) (Millions $) 5
 Net Income (TTM) (Millions $) -105
 Cash Flow (TTM) (Millions $) 43
 Capital Exp. (TTM) (Millions $) 0

Adlai Nortye Ltd




   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
AZN        2.86% 
BMY   -1.46%    
REGN   -8.06%    
UTHR        4.8% 
VRTX   -5.81%    
ZYME   -4.09%    
• View Complete Report
   



Stocks on the Move

Adlai Nortye Ltd Struggles to Keep Pace with the Market A Closer Look at Recent Events

Published Tue, Jun 25 2024 11:16 AM UTC

In the increasingly competitive pharmaceutical industry, Adlai Nortye Ltd has been facing a challenging period as its shares trail behind the overall market performance. With a lackluster 15.22% year-to-date return, the company has been grappling with several events, shaping its trajectory. This article delves into the recent events impacting Adlai Nortye Ltd and analyzes th...

Announcement

Adlai Nortye Ltd. Presents Promising Data on AN0025 in Combination with Definitive Chemoradiotherapy for Unresectable Locally Advanced or Locally Recurrent Esophageal Cancer at ASCO 2024

Published Fri, May 24 2024 1:03 AM UTC

Adlai Nortye Ltd. Presents Encouraging Data on AN0025 in Combination with Definitive Chemoradiotherapy for Esophageal CancerAdlai Nortye Ltd., a clinical-stage biotechnology company, is set to present promising preliminary data at the upcoming American Society of Cancer Oncology (ASCO) Annual Meeting in Chicago. The data pertains to the use of their innovative cancer therap...

Clinical Study

Adlai Nortye Launches Phase II ARTEMIS Trial to Enhance Rectal Cancer Treatment with Palupiprant'

Published Wed, May 22 2024 12:01 PM UTC

Adlai Nortye Initiates Phase II Clinical Trial of Palupiprant for Locally Advanced Rectal Cancer Treatment Singapore, North Brunswick, NJ, and Hangzhou, China, May 22, 2024 Adlai Nortye Ltd. (NASDAQ: ANL), a clinical-stage biotechnology firm specializing in cutting-edge cancer treatments, is pleased to announce the initiation of its Phase II clinical trial for palupiprant (A...










Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com